<DOC>
	<DOC>NCT01948986</DOC>
	<brief_summary>This is a study to evaluate the effect of renal impairment on the pharmacokinetics, pharmacodynamics, safety and tolerability of ertugliflozin in participants with type 2 diabetes mellitus (T2DM) and in healthy participants with normal renal function.</brief_summary>
	<brief_title>Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Body Mass Index (BMI) of approximately 18 to 40 kg/m^2 Stable renal function Male or female not of reproductive potential Female of reproductive potential must agree or have their partner agree to use 2 acceptable methods of contraception Healthy subjects determined to be healthy by investigator screening T2DM participants have a diagnosis of T2DM as per American Diabetes Association guidelines T2DM participants to be on a stable antihyperglycemic regimen with no new drug or drug dosage within 8 weeks of study participation. Variations in daily dose of insulin up to 10% are permitted. A positive urine drug screen for drugs of abuse or recreational drugs Pregnant or nursing females History of abuse of alcohol or illicit drugs Significant renal or urinary disease within 6 months of study participation History of malignancy within the past 5 years basal cell carcinoma of the skin or cervical cancer in situ History of human immunodeficiency virus (HIV) History of blood dyscrasias or any disorders causing hemolysis or unstable red blood cells Any acute disease state (eg, , vomiting, fever, diarrhea) within 7 days before study participation Treatment with an investigational drug within 30 days of study participation Use of herbal supplements within 28 days prior to study participation Any clinically significant malabsorption condition Blood donation (excluding plasma donations) of approximately 1 pint within 56 days prior to study participation History of sensitivity to ertugliflozin or other SodiumGlucose coTransporter 2 (SGLT2) inhibitors History of sensitivity to heparin or heparininduced thrombocytopenia Unwilling or unable to comply with the study Lifestyle Guidelines Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease including clinically relevant and significant drug allergies Use of prescription drugs (hormonal methods of birth control are allowed), vitamins and dietary supplements within 7 days of study participation For T2DM participants, history of type 1 diabetes mellitus or a history of ketoacidosis For T2DM participants, clinically significant electrocardiogram abnormality For T2DM participants, history of myocardial infarction, unstable angina, coronary revascularization, stroke or transient ischemic attack within 3 months of study participation For T2DM participants, heart failure defined as New York Heart Association Functional Class IIIIV For T2DM participants, renal allograft recipients For T2DM participants, requiring dialysis For T2DM participants, strict fluid restriction For T2DM participants, urinary incontinence For T2DM participants, acute renal disease For T2DM participants, significant hepatic, cardiac, or pulmonary disease or clinically nephrotic For T2DM participants, prescription and overthecounter medication that is not taken according to a stable regimen for 7 days before study participation For T2DM participants, on metformin should not be enrolled if their baseline renal function is outside the approved product labeling For T2DM participants receiving any of the following medications within 7 days of study participation: 1. Other SGLT2 inhibitors (eg, dapagliflozin, canagliflozin, empagliflozin); 2. Other injectable antihyperglycemic agents including pramlintide or Glucagonlike peptide1 (GLP1) analogues; 3. Any immunosuppressive drugs, including cyclosporine, tacrolimus, sirolimus; 4. Oral corticosteroids (note that inhaled, nasal and topical corticosteroids are permitted); 5. Any potent drugmetabolizing enzymeinducing drug, including rifampin, phenytoin, and carbamazepine; 6. Probenecid, valproic acid, gemfibrozil.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>